Current State of Melanoma Diagnosis and Treatment
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 4587
Special Issue Editors
Interests: melanoma; dermoscopy; reflectance confocal microscopy; optical coherence tomography; teledermoscopy; histopathology; immunotherapy; targeted therapies; adjuvant therapy; neoadjuvant therapy; thin melanoma; advanced melanoma; metastatic melanoma; predictive factors; adverse events; personalized oncology
Special Issues, Collections and Topics in MDPI journals
Interests: melanoma; non-melanoma skin cancer; dermoscopy; immunotherapy; targeted therapies; predictive factors; skin toxicities; graft versus host disease; allogeneic hemaotopoietic stem cell transplantation
Special Issue Information
Dear Colleagues,
We are pleased to present this Special Issue of Life, aimed at publishing high-quality manuscripts covering new research on the current state of melanoma diagnosis and treatment.
Melanoma is one of the most deadly skin neoplasms, and thus is important to diagnose at the earliest stage. The diagnostic difficulty is due to several factors, such as the shared morphological structures between atypical and growing nevi and thin melanomas, or the wide variety of melanomas that clinically resemble benign or inflammatory lesions—the basis for calling melanoma the great imitator. In addition, it is worth highlighting the aggressively evolving rare histopathological and clinical subtypes of melanomas, increasingly affecting younger patient populations. Currently, dermoscopy is supported by reflective confocal microscopy, but soon, artificial intelligence or optical coherence tomography may become complementary to the standard non-invasive diagnostic methods.
Furthermore, staging procedures in melanoma, including sentinel node biopsy, as well as additional imaging examinations, are of great clinical and prognostic importance.
In recent years, there has been a breakthrough in the treatment of patients with metastatic melanoma, improving survival rates. Among patients who underwent resection of stage III B, IIIC, IIID or stage IV melanoma, adjuvant therapy became the standard of care in the last few years. Highly promising results were produced by recent studies using the neoadjuvant approach for high-risk resectable melanoma. Unfortunately, still many patients do not show a long-term response to targeted therapies or immunotherapy. Thus, new biomarkers and novel therapies are needed to improve the outcomes of melanoma treatment.
We invite all researchers and clinicians involved in the diagnosis and treatment of melanoma to submit articles presenting the results of their research.
Dr. Monika Slowinska
Dr. Grazyna Kaminska – Winciorek
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- dermoscopy
- reflectance confocal microscopy
- optical coherence tomography
- teledermoscopy
- histopathology
- immunotherapy
- targeted therapies
- adjuvant therapy
- neoadjuvant therapy
- thin melanoma
- advanced melanoma
- metastatic melanoma
- predictive factors
- adverse events
- personalized oncology
